Key result
Nifedipine prevented carotid intima-media thickness progression compared to co-amilozide in hypertensive patients completing follow-up (P=0.002), though the intent-to-treat difference was P=0.09.
Why the study?
Does nifedipine prevent carotid IMT progression compared to co-amilozide in hypertensive patients?
Population
439 randomized hypertensive patients
Comparison
Nifedipine 30 mg with optional subsequent… vs Co-amilozide with optional subsequent titration
Design
RCT, randomized
Follow-up
4 years
Authors
Loading...
Should not change practice based on IMT alone; leaves open comparative effects on atherosclerosis progression in hypertension.
RCT (n=439)
randomized
Yes
Does nifedipine prevent carotid IMT progression compared to co-amilozide in hypertensive patients?
p-value: p=0.09 (intent-to-treat); 0.002 (until-end-of-study)
Nifedipine prevents the progression of carotid intima-media thickness compared to co-amilozide in hypertensive patients, despite similar blood pressure reductions.
Simon et al. (2001) conducted an RCT in Hypertension (n=439). Nifedipine vs. Co-amilozide (hydrochlorothiazide 25 mg and amiloride 2.5 mg) was evaluated on IMT progression rate (slope of IMT-time regression) (p=0.09 (intent-to-treat); 0.002 (until-end-of-study)). Nifedipine prevented carotid intima-media thickness progression compared to co-amilozide in hypertensive patients completing follow-up (P=0.002), though the intent-to-treat difference was P=0.09.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: